ES3031633T3 - Annexin a1 n-terminal peptide formulations and methods - Google Patents

Annexin a1 n-terminal peptide formulations and methods

Info

Publication number
ES3031633T3
ES3031633T3 ES21765917T ES21765917T ES3031633T3 ES 3031633 T3 ES3031633 T3 ES 3031633T3 ES 21765917 T ES21765917 T ES 21765917T ES 21765917 T ES21765917 T ES 21765917T ES 3031633 T3 ES3031633 T3 ES 3031633T3
Authority
ES
Spain
Prior art keywords
annexin
pharmaceutical formulation
seq
liquid pharmaceutical
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21765917T
Other languages
English (en)
Spanish (es)
Inventor
Jens Thostrup Bukrinski
Pernille Sønderby Tuelung
Mette Hamborg Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resother Pharma AS
Original Assignee
Resother Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resother Pharma AS filed Critical Resother Pharma AS
Application granted granted Critical
Publication of ES3031633T3 publication Critical patent/ES3031633T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES21765917T 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods Active ES3031633T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20192142 2020-08-21
PCT/EP2021/073186 WO2022038281A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Publications (1)

Publication Number Publication Date
ES3031633T3 true ES3031633T3 (en) 2025-07-10

Family

ID=72193322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21765917T Active ES3031633T3 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Country Status (10)

Country Link
US (2) US20240041977A1 (https=)
EP (3) EP4200320A1 (https=)
JP (1) JP2023539476A (https=)
CN (1) CN116323649A (https=)
AU (1) AU2021327733A1 (https=)
CA (1) CA3192030A1 (https=)
ES (1) ES3031633T3 (https=)
HU (1) HUE071875T2 (https=)
PL (1) PL4200319T3 (https=)
WO (2) WO2022038258A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192030A1 (en) * 2020-08-21 2022-02-24 Resother Pharma A/S Annexin a1 n-terminal peptide formulations and methods
WO2024003338A1 (en) * 2022-06-30 2024-01-04 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
WO2024189056A1 (en) 2023-03-13 2024-09-19 Resother Pharma A/S Annexin a1 administration regime
WO2024189054A1 (en) 2023-03-13 2024-09-19 Resother Pharma A/S Annexin a1 delayed dosing
WO2025083393A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of peptides derived from annexin a1
WO2025083394A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of annexin a1 protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AU2012271453B2 (en) * 2011-06-15 2017-07-06 Resother Pharma Aps Anti-inflammatory pharmaceutical products
JP6117219B2 (ja) * 2011-10-14 2017-04-19 バクスアルタ ゲーエムベーハー 陰イオン交換クロマトグラフィによるタンパク質の精製方法
EP3838285A1 (en) 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)
CN110302176A (zh) * 2019-06-25 2019-10-08 中国人民解放军陆军军医大学 一种抗炎多肽纳米药物及制备方法
CA3192030A1 (en) * 2020-08-21 2022-02-24 Resother Pharma A/S Annexin a1 n-terminal peptide formulations and methods
WO2024003338A1 (en) * 2022-06-30 2024-01-04 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Also Published As

Publication number Publication date
US20240041977A1 (en) 2024-02-08
EP4595950A2 (en) 2025-08-06
US20230295255A1 (en) 2023-09-21
EP4200319B1 (en) 2025-04-16
WO2022038281A1 (en) 2022-02-24
PL4200319T3 (pl) 2025-08-18
AU2021327733A9 (en) 2023-04-27
JP2023539476A (ja) 2023-09-14
AU2021327733A1 (en) 2023-04-20
HUE071875T2 (hu) 2025-09-28
CA3192030A1 (en) 2022-02-24
EP4200319C0 (en) 2025-04-16
WO2022038258A1 (en) 2022-02-24
EP4200320A1 (en) 2023-06-28
EP4200319A1 (en) 2023-06-28
EP4595950A3 (en) 2025-10-29
CN116323649A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
ES3031633T3 (en) Annexin a1 n-terminal peptide formulations and methods
ES2618073T3 (es) Análogos de insulina estabilizados frente a proteasas
ES2344729T3 (es) Interleuquina 2 estabilizada.
RU2332229C2 (ru) Способ введения молекул glp-1
CN1812808B (zh) 稳定化的药物肽组合物
BRPI0410972B1 (pt) Method for increasing the shelf life of a pharmaceutical composition, pharmaceutical composition, and method for treating hyperglycemia
ES2794082T3 (es) Uso de dímeros de IL-22 en la fabricación de medicamentos para tratar la pancreatitis
MX2007000510A (es) Composiciones para suministrar peptido yy y agonistas de pyy.
JP2010530846A (ja) 高温で安定なペプチド製剤
JP6537504B2 (ja) ヘプラペプチドの製剤
ES2679520T3 (es) Formulaciones de moléculas del factor de liberación de hormonas del crecimiento (GRF) con estabilidad mejorada
JP2023166014A (ja) コラーゲン７組成物及びそれを用いる方法
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
KR20150092109A (ko) 주사용 암 조성물
EP2253326B1 (en) Pharmaceutical composition for transnasal administration
JP2023527441A (ja) レナラーゼアゴニスト活性を有する安定なペプチド
CN115605218B (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
US20220241371A1 (en) Peptide formulations and ophthalmic uses thereof
JPWO2016080367A1 (ja) 安定化されたペプチド組成物
RU2833459C2 (ru) Составы аналогов глюкагоноподобного пептида-2 (glp-2)
RU2819934C1 (ru) Жидкие составы аналогов глюкагона
WO2011004054A1 (es) Uso de anhidrasa carbónica ii para la elaboración de un medicamento
JP2001522814A (ja) 増大されたｉｇｆ−ｉ溶解性を提供する組成物
KR20180122144A (ko) 인슐린 비강 전달용 제제